中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2009年
46期
3261-3265
,共5页
胃肿瘤%抗肿瘤联合化疗方案%顺铂%奥沙利铂
胃腫瘤%抗腫瘤聯閤化療方案%順鉑%奧沙利鉑
위종류%항종류연합화료방안%순박%오사리박
Stomach neoplasms%Antineoplastic combined chemotherapy protocols%Cisplatin%Oxaliplatin
目的 系统分析奥沙利铂治疗进展期胃癌的疗效和安全性以及应用前景.方法 通过检索中国数字化期刊全文数据库(CNKI)、万方数据库、维普全文网、美国国家医学图书馆查询系统(PubMed)中近6年来国内外公开发表的文献,收集以奥沙利铂为主的联合方案(试验组)对照顺铂联合方案(对照组)治疗进展期胃癌的临床试验数据,联合药物限定为氟尿嘧啶类(包括卡培他滨)和(或)表阿霉素.使用Review Manager4.2进行有效率、1年生存率、不良反应等方面的荟萃分析.结果 共16篇文献入选,总计2121例胃癌患者,其中试验组1062例,对照组1059例.奥沙利铂为主的联合方案组的有效率(46.3%)较顺铂组(40.6%)高(OR:1.28,P:0.006),1年生存率也高(44.6%比39.3%,OR=1.25,P=0.04);而不良反应中试验组的周围神经毒性的发生率高于对照组(70.6%比21.9%,OR:10.76,P<0.01),贫血(58.0%比70.1%,OR=1.65)和恶心呕吐(61.4%比75.6%,OR=1.32)的发生率则低,差异均有统计学意义(均P<0.05).结论 与既往的顺铂为主的方案相比,奥沙利铂为主的化疗方案在治疗进展期胃癌方面有更好的疗效,相对较安全,患者更易耐受.
目的 繫統分析奧沙利鉑治療進展期胃癌的療效和安全性以及應用前景.方法 通過檢索中國數字化期刊全文數據庫(CNKI)、萬方數據庫、維普全文網、美國國傢醫學圖書館查詢繫統(PubMed)中近6年來國內外公開髮錶的文獻,收集以奧沙利鉑為主的聯閤方案(試驗組)對照順鉑聯閤方案(對照組)治療進展期胃癌的臨床試驗數據,聯閤藥物限定為氟尿嘧啶類(包括卡培他濱)和(或)錶阿黴素.使用Review Manager4.2進行有效率、1年生存率、不良反應等方麵的薈萃分析.結果 共16篇文獻入選,總計2121例胃癌患者,其中試驗組1062例,對照組1059例.奧沙利鉑為主的聯閤方案組的有效率(46.3%)較順鉑組(40.6%)高(OR:1.28,P:0.006),1年生存率也高(44.6%比39.3%,OR=1.25,P=0.04);而不良反應中試驗組的週圍神經毒性的髮生率高于對照組(70.6%比21.9%,OR:10.76,P<0.01),貧血(58.0%比70.1%,OR=1.65)和噁心嘔吐(61.4%比75.6%,OR=1.32)的髮生率則低,差異均有統計學意義(均P<0.05).結論 與既往的順鉑為主的方案相比,奧沙利鉑為主的化療方案在治療進展期胃癌方麵有更好的療效,相對較安全,患者更易耐受.
목적 계통분석오사리박치료진전기위암적료효화안전성이급응용전경.방법 통과검색중국수자화기간전문수거고(CNKI)、만방수거고、유보전문망、미국국가의학도서관사순계통(PubMed)중근6년래국내외공개발표적문헌,수집이오사리박위주적연합방안(시험조)대조순박연합방안(대조조)치료진전기위암적림상시험수거,연합약물한정위불뇨밀정류(포괄잡배타빈)화(혹)표아매소.사용Review Manager4.2진행유효솔、1년생존솔、불량반응등방면적회췌분석.결과 공16편문헌입선,총계2121례위암환자,기중시험조1062례,대조조1059례.오사리박위주적연합방안조적유효솔(46.3%)교순박조(40.6%)고(OR:1.28,P:0.006),1년생존솔야고(44.6%비39.3%,OR=1.25,P=0.04);이불량반응중시험조적주위신경독성적발생솔고우대조조(70.6%비21.9%,OR:10.76,P<0.01),빈혈(58.0%비70.1%,OR=1.65)화악심구토(61.4%비75.6%,OR=1.32)적발생솔칙저,차이균유통계학의의(균P<0.05).결론 여기왕적순박위주적방안상비,오사리박위주적화료방안재치료진전기위암방면유경호적료효,상대교안전,환자경역내수.
Objective To analyze whether Oxaliplatin (OXA) is effective in advanced gastric cancer.Methods Clinical trials of OXA-based chemotherapy (treatment group) versus DDP-based chemotherapy (control group) in advanced gastric cancer which published in 6 years were retrieved from China National Knowledge Infrastructure (CNKI),Wanfang Data,VIP information database and PubMed of U.S.National Library of Medicine and NIH.Review Manager 4.2 was used for meta-analysis and main outcome measure ineluded objective response rate.survival and toxicities.Results There were 2121 patients (1062 cases in treatment group and 1059 cases in control group) from 16 controlled clinical trials were enrolled.Response rate increased (46.3% vs 40.6%.OR-1.28,P=0.006)and 1-year survival rate increased (44.6% vs 39.3%,OR=1.25,P=0.04) in treatment group than that of control group.Peripheral neurotoxity was more frequently observed in treatment group (70.6% vs 21.9%,OR=10.76,P<0.01) while anemia and nausea/vomiting were reversed (58.0% vs 70.1%,61.4% vs 75.6% respectively,both P<0.05).Conclusion Oxaliplatin-based chemotherapy is well-tolerated and more effective than cisplatin in advanced gastric cancer.
